Drug intelligence / Profile preview

cefoperazone + sulbactam

Development stage
Phase 4
Lead developer
Pfizer
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Cefoperazone + sulbactam is a combination antibiotic consisting of two active components: cefoperazone, a third-generation cephalosporin (β-lactam) antibiotic, and sulbactam, a β-lactamase inhibitor. Cefoperazone acts by binding to penicillin-binding proteins in bacterial cell walls and inhibiting the final stage of cell wall synthesis, leading to bacterial lysis. It is effective against a broad range of gram-negative and some gram-positive bacteria. However, many bacteria produce β-lactamases that can degrade β-lactams like cefoperazone. Sulbactam inhibits these enzymes irreversibly, protecting cefoperazone from degradation and extending its antibacterial spectrum to include organisms resistant to other β-lactams. The combination is used for serious infections such as respiratory tract infections (upper and lower), urinary tract infections (upper and lower), intra-abdominal infections, septicemia, meningitis, skin infections, bone infections, endometritis, and others[1][3][5][6].

Brand names
MagnexSulcefozone
Other names
cefoperazone/sulbactamsulbactam sodium/cefoperazone sodium
02

Targets

Neuraminidase

Beyond the preview

Go deeper on cefoperazone + sulbactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefoperazone + sulbactam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call